- Home
- UMAC vs PRCT Comparison
UMAC vs PRCT Comparison
Compare UMAC & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UMAC | PRCT |
|---|---|---|
| Founded | 2019 | 2009 |
| Country | United States | United States |
| Employees | N/A | 888 |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | UMAC | PRCT |
|---|---|---|
| Price | $22.97 | $20.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $20.00 | ★ $35.44 |
| AVG Volume (30 Days) | ★ 4.3M | 930.8K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.73 | 1.71 |
| EPS | ★ 0.06 | N/A |
| Revenue | $11,199,217.00 | ★ $308,054,000.00 |
| Revenue This Year | $115.39 | $31.34 |
| Revenue Next Year | $101.44 | $24.52 |
| P/E Ratio | $405.50 | ★ N/A |
| Revenue Growth | ★ 101.23 | 37.22 |
| 52 Week Low | $7.25 | $16.67 |
| 52 Week High | $34.93 | $40.10 |
Technical Indicators
Market Signals| Indicator | UMAC | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 47.71 | 45.20 |
| Support Level | $22.12 | $19.87 |
| Resistance Level | $25.94 | $29.27 |
| Average True Range (ATR) | 1.80 | 1.04 |
| MACD | -0.32 | -0.12 |
| Stochastic Oscillator | 24.83 | 10.08 |
Price Performance
Historical ComparisonAbout UMAC Unusual Machines Inc.
Unusual Machines Inc is engaged in manufactures and sells drone components and drones across a diversified brand portfolio through business-to-business (B2B) sales and a curated retail channel.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.